• Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing
  • GSK3β is a new therapeutic target for myotonic dystrophy type 1
  • The <italic>Nbeal2<sup>−/−</sup></italic> mouse as a model for the gray platelet syndrome

 Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing

Oscar Hernández-Hernández, Géraldine Sicot, Diana M. Dinca, Aline Huguet, Annie Nicole, Luc Buée, Arnold Munnich, Nicolas Sergeant, Geneviève Gourdon and Mário Gomes-Pereira

View Article

 GSK3β is a new therapeutic target for myotonic dystrophy type 1

Christina Wei, Karlie Jones, Nikolai A Timchenko and Lubov Timchenko

View Article

 The Nbeal2−/− mouse as a model for the gray platelet syndrome

Carsten Deppermann, Paquita Nurden, Alan T Nurden, Bernhard Nieswandt and David Stegner

View Article

Explore Rare Diseases

Recent Articles